TP53 and cancer: Interestingly, FOXM1 expression enhances resistance to other RCD pathways such as ferroptosis (discussed below in “Effects of p53 mutation on ferroptosis”), suggesting that FOXM1 inhibition could activate multiple RCD pathways in p53-mutant cancers.